Literature DB >> 30723096

Simultaneous LC/MS/MS quantification of eight apolipoproteins in normal and hypercholesterolemic mouse plasma.

Richard Wagner1, Julia Dittrich1,2, Joachim Thiery1,2, Uta Ceglarek3,2, Ralph Burkhardt3,2,4.   

Abstract

Apolipoproteins are major structural and functional constituents of lipoprotein particles. As modulators of lipid metabolism, adipose tissue biology, and energy homeostasis, apolipoproteins may serve as biomarkers or potential therapeutic targets for cardiometabolic diseases. Mice are the preferred model to study metabolic disease and CVD, but a comprehensive method to quantify circulating apolipoproteins in mice is lacking. We developed and validated a targeted proteomics assay to quantify eight apolipoproteins in mice via proteotypic signature peptides and corresponding stable isotope-labeled analogs. The LC/MS/MS method requires only a 3 µl sample volume to simultaneously determine mouse apoA-I, apoA-II, apoA-IV, apoB-100, total apoB, apoC-I, apoE, and apoJ concentrations. ApoB-48 concentrations can be calculated by subtracting apoB-100 from total apoB. After we established the analytic performance (sensitivity, linearity, and imprecision) and compared results for selected apolipoproteins against immunoassays, we applied the method to profile apolipoprotein levels in plasma and isolated HDL from normocholesterolemic C57BL/6 mice and from hypercholesterolemic Ldl-receptor- and Apoe-deficient mice. In conclusion, we present a robust, quantitative LC/MS/MS method for the multiplexed analysis of eight apolipoproteins in mice. This assay can be applied to investigate the effects of genetic manipulation or dietary interventions on apolipoprotein levels in plasma and isolated lipoprotein fractions.
Copyright © 2019 Wagner et al.

Entities:  

Keywords:  animal models; lipoproteins; liquid chromatography; mass spectrometry; proteomics; quantitation

Mesh:

Substances:

Year:  2019        PMID: 30723096      PMCID: PMC6446716          DOI: 10.1194/jlr.D084301

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

Review 1.  Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families.

Authors:  P Alaupovic
Journal:  Prog Lipid Res       Date:  1991       Impact factor: 16.195

Review 2.  The biological impact of mass-spectrometry-based proteomics.

Authors:  Benjamin F Cravatt; Gabriel M Simon; John R Yates
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

3.  LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice.

Authors:  Sandra A Schreyer; Cynthia Vick; Theodore C Lystig; Paul Mystkowski; Renée C LeBoeuf
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-01       Impact factor: 4.310

4.  High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.

Authors:  B J Van Lenten; A C Wagner; D P Nayak; S Hama; M Navab; A M Fogelman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

5.  Developmental and age-related changes in apolipoprotein B mRNA editing in mice.

Authors:  K Higuchi; K Kitagawa; K Kogishi; T Takeda
Journal:  J Lipid Res       Date:  1992-12       Impact factor: 5.922

6.  Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice.

Authors:  Susanna M Hofmann; Diego Perez-Tilve; Todd M Greer; Beth A Coburn; Erin Grant; Joshua E Basford; Matthias H Tschöp; David Y Hui
Journal:  Diabetes       Date:  2007-10-03       Impact factor: 9.461

7.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

8.  Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.

Authors:  Matthew J McQueen; Steven Hawken; Xingyu Wang; Stephanie Ounpuu; Allan Sniderman; Jeffrey Probstfield; Krisela Steyn; John E Sanderson; Mohammad Hasani; Emilia Volkova; Khawar Kazmi; Salim Yusuf
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

9.  Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice.

Authors:  Iordanes Karagiannides; Rami Abdou; Aikaterini Tzortzopoulou; Peter J Voshol; Kyriakos E Kypreos
Journal:  FEBS J       Date:  2008-08-27       Impact factor: 5.542

10.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

View more
  2 in total

1.  Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration.

Authors:  Huu-Hien Huynh; Amandine Bœuf; Maxence Derbez-Morin; Anne-Marie Dupuy; Béatrice Lalere; Vincent Delatour; Joëlle Vinh
Journal:  Anal Bioanal Chem       Date:  2021-05-14       Impact factor: 4.142

2.  Simultaneous quantification of apolipoproteins A-I, E, and J in human plasma by LC-MS/MS for clinical application to diabetes mellitus complicated with cardiovascular disease.

Authors:  Pengfei Li; Yuting Cong; Wen Zhang; Lefeng Wang; Lulu Ren; Xin Li; Song Yang; Zhiyong Zhang; Guoqing Li; Lihong Liu
Journal:  RSC Adv       Date:  2022-06-06       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.